Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Anika Therapeutics (ANIK) Cash from Operations (2016 - 2026)

Anika Therapeutics has reported Cash from Operations over the past 17 years, most recently at 4846000.0 for Q1 2026.

Quarterly Cash from Operations fell 3627.69% to 4846000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 6472000.0 through Mar 2026, up 19.87% year-over-year, with the annual reading at 11188000.0 for FY2025, 107.07% up from the prior year.
Cash from Operations was 4846000.0 for Q1 2026 at Anika Therapeutics, down from 4637000.0 in the prior quarter.
Over five years, Cash from Operations peaked at 6870000.0 in Q3 2025 and troughed at 8293000.0 in Q2 2023.
The 5-year median for Cash from Operations is 481000.0 (2022), against an average of 845058.82.
Year-over-year, Cash from Operations soared 656.34% in 2023 and then tumbled 3627.69% in 2026.
A 5-year view of Cash from Operations shows it stood at 481000.0 in 2022, then soared by 656.34% to 3638000.0 in 2023, then tumbled by 56.51% to 1582000.0 in 2024, then soared by 193.11% to 4637000.0 in 2025, then crashed by 204.51% to 4846000.0 in 2026.
Per Business Quant, the three most recent readings for ANIK's Cash from Operations are 4846000.0 (Q1 2026), 4637000.0 (Q4 2025), and 6870000.0 (Q3 2025).